LexaGene Appoints Greg Dale to Vice President of Product Development and Manufacturing

VANCOUVER, British Columbia, Jan. 25, 2018 -- LexaGene Holdings Inc. (OTCQB:LXXGF) (TSX-V:LXG) (the “Company”), a biotechnology company that develops instrumentation for pathogen detection, today announced the appointment of Mr. Greg Dale to the role of Vice President of Product Development and Manufacturing at LexaGene. This follows the recent completion of LexaGene’s prototype assembly for what will be the world’s first fully automated, open-access pathogen detection system, which will be used across the food safety, veterinary and human clinical diagnostics industries.

“The deep industry knowledge that Mr. Dale brings to LexaGene comes at an opportune time during this rapid growth phase where we plan to build and deliver beta instruments and begin the sale of our commercial system before the end of the year,” said Dr. Jack Regan, LexaGene’s CEO. “Greg’s entrepreneurial leadership experience with successfully commercializing complex technology products makes him a perfect fit for our team and further supports our continued goal of being a market-disrupting, thought-leading company.”

Mr. Dale has developed and manufactured more than a dozen products to date and is listed as an inventor on 28 issued U.S. patents on PCR and microfluidics devices. His medical device and in-vitro diagnostics product development experience includes work with instruments, microfluidics, sensors, disposables, reagents, wearables and implantables. Mr. Dale most recently served as Vice President, Product Development, Manufacturing and Quality at Emulate LLC; prior to Emulate, Mr. Dale served as General Manager and Senior Director of NGS (Next-Generation Sequencing) Engineering at Qiagen, where he designed, developed and launched the Qiagen GeneReader NGS system using agile development methods. He also managed and coordinated the site engineering and project management activities in the development of next-generation DNA sequencing products with global R&D and manufacturing teams.

“Mr. Dale’s unique skillset is difficult to find and extremely valuable for LexaGene as we continue along the path of bringing our innovative pathogen detection system to key markets that are in dire need of more effective solutions,” concluded Dr. Regan. “As our Company’s technology is set to completely transform the way that food safety, vet diagnostics, water quality monitoring and other markets get critical answers in less time, we are laser-focused on building out the most strategic, results-oriented team possible, from both a business and scientific perspective, to make this a reality in the near future.”

To be added to the LexaGene email distribution list, please subscribe on the LexaGene website here.

About LexaGene Holdings Inc.

LexaGene is a biotechnology company developing the very first fully automated pathogen detection platform that is open-access.  The open-access feature will empower end-users to target any pathogen of interest, as they can load their own real-time PCR assays onto the instrument for customized pathogen detection.  End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, and press ‘go’. The instrument is expected to offer excellent sensitivity, specificity, and breadth of pathogen detection.  The instrument will be able to process six samples at a time, in an on-demand fashion, returning results in about 1 hour.  The company expects to sell its technology in the food safety, veterinary diagnostics, water quality monitoring, and aquaculture pathogen surveillance markets.

The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors -- including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues -- that could cause actual results to differ materially from the Company's expectations as disclosed in the Company's documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Media Contacts
Caitlin Kasunich / Amy Singh
KCSA Strategic Communications
212.896.1241 / 212.896.1207
[email protected]/ [email protected]